AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35480078 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated risk prediction model for malignant esophageal lesions
Number of subjects: 20000
Study 35481400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 43
Study 35481559 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for automatic detection of atrial fibrillation using a single-lead electrocardiogram from a smartwatch
Number of subjects: 262
Study 35481559 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lead electrocardiogram
Number of subjects: 262
Study 35481819 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention for caregivers of individuals with advanced PD
Number of subjects: 34
Study 35482080 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 17
Study 35482127 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous GM-CSF-secreting breast cancer vaccine
Number of subjects: 22
Study 35482392 — intervention group
Group type: EXPERIMENTAL
Intervention: Eir web-based communication tool for symptom registration at home
Number of subjects: 134
Study 35482408 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy
Number of subjects: 30
Study 35482408 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy with highly neutralizing plasma
Number of subjects: 30
Study 35482408 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy with high neutralizing antibodies
Number of subjects: 30
Study 35482538 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (15 μg/m)
Number of subjects: 0
Study 35482538 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 35482538 — intervention group
Group type: COMPARATOR
Intervention: HC3
Number of subjects: 0
Study 35482768 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting PA guidelines (MVPA ≥30 min·d -1)
Number of subjects: 100
Study 35482768 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 100
Study 35482768 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100
Study 35482768 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity PA (MVPA)
Number of subjects: 100
Study 35482910 — intervention group
Group type: EXPERIMENTAL
Intervention: TETA-2HCl treatment
Number of subjects: 77
Study 35483358 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 35483358 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR inhibitors
Number of subjects: 0
Study 35483396 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus intensive chemotherapy
Number of subjects: 279
Study 35483396 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy alone
Number of subjects: 279
Study 35483431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sayana® Press injected every 4 months
Number of subjects: 750
Study 35483480 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon undilatable lesions
Number of subjects: 558
Study 35483736 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 PCR-positive patients (n=28)
Number of subjects: 48
Study 35483736 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 PCR-negative exposed controls (n=20)
Number of subjects: 48
Study 35483792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4740
Study 35483792 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4740
Study 35483796 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4776
Study 35483876 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35484319 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 21
Study 35484319 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg intravenously every 2 weeks
Number of subjects: 21
Study 35484319 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended dose of 15 mg/kg every 2 weeks for patients aged < 12 years or weighing < 40 kg
Number of subjects: 21
Study 35484319 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended adult flat dose of 800 mg every 2 weeks for patients aged ≥ 12 years and weighing ≥ 40 kg
Number of subjects: 21
Study 35484400 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 529
Study 35484400 — intervention group
Group type: EXPERIMENTAL
Intervention: regorafenib
Number of subjects: 529
Study 35484469 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal meningitis patients
Number of subjects: 111
Study 35484592 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress due to indistinct organization and conflicts
Number of subjects: 232
Study 35484592 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress due to individual demands and commitment
Number of subjects: 232
Study 35484592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low influence at work
Number of subjects: 232
Study 35484592 — intervention group
Group type: EXPERIMENTAL
Intervention: High interference between work and leisure time
Number of subjects: 232
Study 35484592 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress due to both indistinct organization and conflicts and individual demands and commitment
Number of subjects: 232
Study 35484614 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS) or combined modality EBUS/endoscopic ultrasound (EUS-B) for staging
Number of subjects: 10
Study 35484614 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mediastinal staging
Number of subjects: 10
Study 35484649 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab (anti-CD6 monoclonal antibody)
Number of subjects: 95
Study 35484649 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab
Number of subjects: 95
Study 35484649 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study 35484817 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily enoxaparin (initial dose: 0.5mg/kg per dose; max: 60mg; target anti-Xa activity: 0.20-0.49IU/mL)
Number of subjects: 40
Study 35484817 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily enoxaparin
Number of subjects: 40
Study 35485211 — intervention group
Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel
Number of subjects: 0
Study 35485211 — intervention group
Group type: COMPARATOR
Intervention: conventional care
Number of subjects: 0
Study 35485232 — intervention group
Group type: EXPERIMENTAL
Intervention: LRP patients
Number of subjects: 390
Study 35485232 — intervention group
Group type: COMPARATOR
Intervention: non-LRP patients
Number of subjects: 390
Study 35485234 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred and thriving-promoting intervention (staff educational programme)
Number of subjects: 292
Study 35485234 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 292
Study 35485327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ventilation and perfusion (LVP) by LVP scintigraphy
Number of subjects: 20
Study 35485327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m-labeled albumin-gated blood-pool scintigraphy
Number of subjects: 20
Study 35485802 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up prevalence of any disorder
Number of subjects: 8996
Study 35485802 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of probable mental disorders
Number of subjects: 8996
Study 35485802 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of mental disorders
Number of subjects: 8996
Study 35485802 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Prioritising Covid-19 patients
Number of subjects: 8996
Study 35485802 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Personal health-related stress
Number of subjects: 8996
Study 35485802 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Interpersonal stress
Number of subjects: 8996
Study 35485802 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Significant income loss
Number of subjects: 8996
Study 35485908 — intervention group
Group type: EXPERIMENTAL
Intervention: Factory-calibrated Continuous Glucose Monitor (CGM)
Number of subjects: 20
Study 35485920 — intervention group
Group type: COMPARATOR
Intervention: Obsessive-compulsive disorder (OCD) group
Number of subjects: 200
Study 35485920 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 200
Study 35485920 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants with OCD
Number of subjects: 200
Study 35485920 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 200
Study 35485937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine 18 fluoromisonidazole (18F-FMISO) imaging
Number of subjects: 0
Study 35485937 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35486436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 20
Study 35486436 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (control)
Number of subjects: 20
Study 35486437 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (standard clinical practice + mobile app)
Number of subjects: 0
Study 35486437 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice (control group)
Number of subjects: 0
Study 35486475 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin plus intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and 1-year midostaurin maintenance therapy
Number of subjects: 440
Study 35486475 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin plus intensive chemotherapy
Number of subjects: 440
Study 35486638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m2 as a 1-hour infusion every 3 weeks
Number of subjects: 28
Study 35487034 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 22
Study 35487034 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale (EDSS)
Number of subjects: 22
Study 35487034 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed 25-foot walk (T25FW)
Number of subjects: 22
Study 35487105 — intervention group
Group type: EXPERIMENTAL
Intervention: Results communicated by postal letter
Number of subjects: 1900
Study 35487256 — intervention group
Group type: EXPERIMENTAL
Intervention: MeMed BV® and MeMed Key®
Number of subjects: 0
Study 35487387 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 35487387 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 35487538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 35487538 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35487718 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsies (peripheral blood and urine samples) collected every 6 or 12 months for 11 years, including detection of circulating tumour cells, circulating tumour DNA (ctDNA), exosomal micro-RNA (miRNA), miRNA in Tumour Educated Platelet and metabolomic profiles.
Number of subjects: 1455
Study 35487718 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) collected annually, including 10 PROM questionnaires.
Number of subjects: 1455
Study 35487718 — intervention group
Group type: COMPARATOR
Intervention: Control group of 200 women without cancer aged 25-70 years providing the same data.
Number of subjects: 1455
Study 35487733 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (defined as the concomitant use of five or more medications, excluding vitamins or dietary supplements)
Number of subjects: 2157
Study 35487733 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2157
Study 35487733 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater BMI
Number of subjects: 2157
Study 35487733 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of comorbidities
Number of subjects: 2157
Study 35487733 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 2157
Study 35487733 — intervention group
Group type: EXPERIMENTAL
Intervention: City of residence (Coimbra)
Number of subjects: 2157
Study 35487733 — intervention group
Group type: EXPERIMENTAL
Intervention: City of residence (Geneva)
Number of subjects: 2157
Study 35487733 — intervention group
Group type: EXPERIMENTAL
Intervention: City of residence (Toulouse)
Number of subjects: 2157
Study 35487735 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to any traumatic event
Number of subjects: 677
Study 35487735 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to non-partner rape
Number of subjects: 677
Study 35487735 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 677
Study 35487745 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity level
Number of subjects: 452
Study 35487814 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus vaccine (9vHPV)
Number of subjects: 1990
Study 35487845 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (SC trastuzumab) administered every 3 weeks for 18 cycles as adjuvant therapy
Number of subjects: 2573
Study 35487845 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab with no chemotherapy
Number of subjects: 2573
Study 35487845 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab with concurrent chemotherapy
Number of subjects: 2573
Study 35487845 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab with sequential chemotherapy
Number of subjects: 2573
Study 35487894 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair-modified ergometer rowing exercise (REMW), 3 times weekly for up to 30 minutes per session
Number of subjects: 8
Study 35487894 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair-modified ergometer rowing exercise (REMW)
Number of subjects: 8
Study 35488054 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness
Number of subjects: 0
Study 35488127 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AF ablation
Number of subjects: 25963
Study 35488127 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 25963
Study 35488129 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONG contractions of the hand/wrist
Number of subjects: 14
Study 35488129 — intervention group
Group type: EXPERIMENTAL
Intervention: WEAK contractions of the hand/wrist
Number of subjects: 14
Study 35488129 — intervention group
Group type: COMPARATOR
Intervention: CONTROL condition
Number of subjects: 14
Study 35488256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning workers (hospital and university groups)
Number of subjects: 167
Study 35488256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning workers (hospital and housekeeper groups)
Number of subjects: 167
Study 35488256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning workers
Number of subjects: 167
Study 35488256 — intervention group
Group type: EXPERIMENTAL
Intervention: University group
Number of subjects: 167
Study 35488256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning workers (overall)
Number of subjects: 167
Study 35488256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital cleaning workers
Number of subjects: 167
Study 35488256 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of time performing cleaning work
Number of subjects: 167
Study 35488261 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 72
Study 35488283 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA gene expression
Number of subjects: 33
Study 35488283 — intervention group
Group type: EXPERIMENTAL
Intervention: uPA gene expression
Number of subjects: 33
Study 35488283 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1 gene expression
Number of subjects: 33
Study 35488283 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-2 gene expression
Number of subjects: 33
Study 35488295 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIO intervention (app-based cognitive-behavioral pain self-management program)
Number of subjects: 50
Study 35488337 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids plus long-acting beta agonists
Number of subjects: 4978
Study 35488337 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry grading
Number of subjects: 4978
Study 35488337 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD classification
Number of subjects: 4978
Study 35488422 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled lockdown with social distancing (study group)
Number of subjects: 5800000
Study 35488422 — intervention group
Group type: COMPARATOR
Intervention: No controlled lockdown and social distancing (reference group)
Number of subjects: 5800000
Study 35488717 — intervention group
Group type: EXPERIMENTAL
Intervention: Homecare (yes)
Number of subjects: 406
Study 35488717 — intervention group
Group type: COMPARATOR
Intervention: No homecare (no)
Number of subjects: 406
Study 35488717 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission (yes)
Number of subjects: 406
Study 35488717 — intervention group
Group type: COMPARATOR
Intervention: No readmission (no)
Number of subjects: 406
Study 35488718 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression score of ENOX1
Number of subjects: 425
Study 35488718 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression scores of MAN2A1 and PCGF3
Number of subjects: 425
Study 35488900 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib (100 mg once daily) + azacitidine
Number of subjects: 72
Study 35488938 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening by Professionals (ProfScreen)
Number of subjects: 4172
Study 35488938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4172
Study 35488938 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending the ProfScreen interview
Number of subjects: 4172
Study 35489133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure (systolic BP ≤ 110 mm Hg and/or diastolic BP ≤ 70 mm Hg)
Number of subjects: 1394
Study 35489133 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure (systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg)
Number of subjects: 1394
Study 35489133 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug use
Number of subjects: 1394
Study 35489233 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (REGO) 160 mg/day for 21 days of a 28-day cycle
Number of subjects: 55
Study 35489377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir dispersible tablets (5 mg)
Number of subjects: 181
Study 35490124 — intervention group
Group type: EXPERIMENTAL
Intervention: Performed PCI
Number of subjects: 400
Study 35490124 — intervention group
Group type: COMPARATOR
Intervention: Deferred PCI
Number of subjects: 400
Study 35490124 — intervention group
Group type: EXPERIMENTAL
Intervention: Performed PCI in preserved CFR cohort
Number of subjects: 400
Study 35490124 — intervention group
Group type: COMPARATOR
Intervention: Deferred PCI in preserved CFR cohort
Number of subjects: 400
Study 35490124 — intervention group
Group type: EXPERIMENTAL
Intervention: Performed PCI in depressed CFR cohort
Number of subjects: 400
Study 35490124 — intervention group
Group type: COMPARATOR
Intervention: Deferred PCI in depressed CFR cohort
Number of subjects: 400
Study 35490339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy-pacemaker (CRT-P)
Number of subjects: 1738
Study 35490339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CRT-P)
Number of subjects: 1738
Study 35490596 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI and BP in all children
Number of subjects: 2100
Study 35490596 — intervention group
Group type: EXPERIMENTAL
Intervention: Every unit increase in SBP
Number of subjects: 2100
Study 35490596 — intervention group
Group type: EXPERIMENTAL
Intervention: Every unit increase in DBP
Number of subjects: 2100
Study 35490596 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2100
Study 35490596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2100
Study 35490596 — intervention group
Group type: EXPERIMENTAL
Intervention: Black ethnicity
Number of subjects: 2100
Study 35490596 — intervention group
Group type: COMPARATOR
Intervention: Black SA children
Number of subjects: 2100
Study 35490915 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain structural components associated with low mid-life performance across multiple cognitive domains, decline in reasoning, but maintenance of fluency abilities.
Number of subjects: 3
Study 35490915 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain structural components associated with low mid-life performance in fluency and memory, but retention of multiple abilities.
Number of subjects: 3
Study 35490915 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of latent variables predicting future cognition.
Number of subjects: 3
Study 35491417 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 30
Study 35491417 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 30
Study 35491419 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 109
Study 35491419 — intervention group
Group type: COMPARATOR
Intervention: VKA
Number of subjects: 109
Study 35491421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquitous priority infections diagnosed in participants (total 452, 23.5%)
Number of subjects: 1922
Study 35491421 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs) for S. Typhi
Number of subjects: 1922
Study 35491421 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs) for leptospirosis
Number of subjects: 1922
Study 35491432 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus TQB2450
Number of subjects: 66
Study 35491481 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac artery EVT
Number of subjects: 1364